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Abstract
Patients with liver cirrhosis are characterized by decreased synthesis of both pro- and anticoagulant
factors, and recently there has been evidence of normal generation of thrombin resulting in a near normal
haemostatic balance. Although it is generally recognized that bleeding is the most common clinical
manifestation as a result of decreased platelet function and number, diminished clotting factors and
excessive fibrinolysis, hypercoagulability may play an under recognized but important role in many
aspects of chronic liver disease. In fact, they can encounter thrombotic complications such as portal vein
thrombosis, occlusion of small intrahepatic vein branches and deep vein thrombosis (DVT). In particular,
patients with cirrhosis appear to have a higher incidence of unprovoked DVT and pulmonary embolism
(PE) compared with the general population. In dedicated studies, the incidence of DVT/PE ranges from
0.5% to 1.9%, similar to patients without comorbidities, but lower than patients with other chronic
diseases (i.e, renal or heart disease). Surprisingly, standard coagulation laboratory parameters are not
associated with a risk of developing DVT/PE; however, with multivariate analysis, serum albumin level was
independently associated with the occurrence of thrombosis. Moreover, patients with chronic liver
disease share the same risk factors as the general population for DVT/PE, and specifically, liver resection
can unbalance the haemostatic equilibrium towards a hypercoagulable state. Current guidelines on
antithrombotic prophylaxis do not specifically comment on the cirrhotic population as a result of the
perceived risk of bleeding complications but the cirrhotic patient should not be considered as an
auto-anticoagulated patient. Therefore, thromboprophylaxis should be recommended in patients with
liver cirrhosis at least when exposed to high-risk conditions for thrombotic complications. Low molecular
weight heparins (LWMHs) seem to be relatively safe in this group of patients; however, when important
risk factors for bleeding are present, graduated compression stockings or intermittent pneumatic com-
pression should be considered.
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Introduction
The liver plays several key roles in blood coagulation and is
involved in both primary and secondary haemostasis.1,2 Hepato-
cytes are the site of synthesis of all coagulation factors and their
inhibitors except for von Willebrand factor.3
Liver damage is commonly associated with impairment of
coagulation, when hepatic reserve is poor. The haemostatic system
is in a delicate balance between prothrombotic and antithrom-
botic processes, aiming to prevent excessive blood loss from
injured vessels and to prevent spontaneous thrombosis. Liver
failure is accompanied by multiple changes in the haemostatic
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system, because of reduced plasma levels of procoagulant and
anticoagulant clotting factors synthesized by hepatocytes and
sinusoidal cells.4,5 Therefore the clinical result (thrombosis or
bleeding) depends on the derangement in the balance of these
complex mechanisms.
Although it is generally recognized that bleeding is the most
common clinical manifestation as a result of decreased platelet
function and number, diminished clotting factors and excessive
fibrinolysis, hypercoagulability may have a poorly appreciated but
important role in many aspects of chronic liver disease.
Clinically, thrombotic complications can be observed in
patients with cirrhosis, despite standard coagulation laboratory
tests revealing a prolonged PT/INR, which is perceived normally
to be indicative of a bleeding tendency.6 Portal vein thrombosis
(PVT) is a common complication of liver cirrhosis, with an inci-
dence of about 10–15%, and probably as a result of multiple local
and systemic factors including a (relative) hypercoagulable state.7
Genetic prothrombotic predisposition is found in about 70% of
patients with PVT, compared with 8% in those without.8,9
It is also known that coagulation disorders associated with
chronic liver disease, especially in liver cirrhosis, can promote
further liver damage.Wanless and colleagues have clearly demon-
strated histopathological evidence of secondary hepatic damage as
a result of thrombosis and occlusion of intrahepatic venous blood
vessels.10 Moreover there is evidence from both clinical observa-
tions and animal studies suggesting that a hypercoagulable and
hypofibrinolytic state can promote liver fibrosis.11
During the concomitant presence of portopulmonary syn-
drome and portal hypertension, the local procoagulant state con-
tributes to the obliterative arteriopathy in cirrhotic patients with
this complication.12
Moreover, the risk of DVT and PE is not well documented in
cirrhotic patients, yet is reported.13 A summary of thrombotic
conditions that can occur in patients with liver disease with cor-
responding aetiological factors is represented in Table 1. Based on
this clinical evidence, the patient with cirrhosis cannot be con-
sidered to be protected from thrombotic risk as a result of
auto-anticoagulation.
Laboratory evaluation of coagulation in patients with liver
disease shows normal thrombin generation in platelet poor
and platelet rich plasma, given a platelet count greater than
80 000/ml.14 Similarly, thromboelastography showed no differ-
ences in coagulation parameters in cirrhotic patients compared
with healthy controls.15
Standard laboratory tests are not useful in evaluating the coagu-
lation status in patients with chronic liver disease. The prothrom-
bin time does not portray adequately the in vivo haemostatic
status in patients with liver disease, as the test is only sensitive for
procoagulant factors. For this reason, liver disease patients with a
prolonged PT can have normal thrombin generation, as antico-
agulant factors are also deficient in these patients. Moreover, the
international normalized ratio (INR) has been shown to be an
inconsistent tool in this group of patients, as there may be
substantial variation from one laboratory to another in the INR of
a single patient16 using different thromboplastins, which are cali-
brated with methods likely unsuitable for cirrhotic patients.
Incidence of DVT and PE in patients with liver
cirrhosis
Venous thromboembolism (VTE) is a major national health
problem, with at least 200 000 new cases per year in the United
States and an incidence of 74.5 per 100 000 persons per year in the
United Kingdom. Prevention is essential to reduce the incidence
of VTE and the subsequent high risk of mortality. Endogenous
coagulopathy in hospitalized cirrhotic patients is often considered
to be protective against pulmonary thromboembolism and DVT
despite the lack of empirical data to confirm this hypothesis.
In a small case–control study from United States, Heit and
colleagues found a substantially reduced relative risk of 0.1 of VTE
in patients with serious liver disease.17 On the other hand, a recent
case–control study from the United Kingdom showed a non-
significant increased relative risk of 1.7 of VTE in patients with
chronic liver disease.18 However, these two studies were not
properly designed to evaluate the incidence of VTE in patients
with cirrhosis.
A nationwide population-based study undertaken in Denmark,
which evaluated more than 99 000 patients with thromboembo-
lism, showed that patients with chronic liver disease are at greater
risk of VTE ranging from 1.7 to 1.9 in patients with cirrhotic and
non-cirrhotic liver disease, respectively.19 In this study, a sub-
analysis evaluating the risk of unprovoked VTE (occurrence of
VTE 90 days after any risk factor) revealed that cirrhosis and liver
Table 1 Evidences of thrombotic events and aetiologies' in patients
with liver diseases
Portal vein thrombosis Local factor (flow obstruction)
Inflammation
Systemic prothrombotic conditions
Deep vein thrombosis and
pulmonary embolism
Decrease synthesis of anticoagulant
factors
Systemic increase of proinflammatory
cytokines
Progression of cirrhosis by
parenchymal
microvascular thrombosis
Parenchymal extinction
Extracorporeal circuit
thrombosis
Mechanical obstruction
Inflammation
Contact activation of coagulation
cascade
Pulmonary hypertension Endothelial dysfunction (shear stress)
Microvascular thrombosis
Metabolic syndrome and
NASH
Atherosclerosis
Increased systemic inflammation
Increased procoagulant factor levels
correlated to insulin resistance
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disease carry an even greater risk of VTE with an odds ratio (OR)
of 2.1 and 3.6 if age is less than 55 years. Interestingly, the authors
also found that the relative risk (RR) for VTE was similarly
elevated in a sub-analysis of patients with hepatocellular carci-
noma within the group of patients with cirrhosis (RR 1.8).19
However, this population-based study had no information on
patient characteristics or the severity of liver disease.
To date, three studies have been published which aimed to
investigate specifically the prevalence of DVT and PE in patients
with liver cirrhosis, two case–control studies13,20 and one retro-
spective study21 in three different institutions.
Overall, 24 037 cirrhotic patients and 12 518 controls (includ-
ing 113 cirrhotic patients without DVT) were studied and the
incidence of DVT or PE ranged from 0.5% to 1.9% across the
different studies. In particular, in the larger population evaluated
(which was the one with the lower incidence) 21% of patients
received antithrombotic prophylaxis with drugs (7%) or compres-
sion devices (14%) at the time they experienced the thrombotic
event.13 Thus, even patients with a prolonged PT who receive
antithrombotic drugs can develop a venous thrombosis.
Gulley et al. performed a matched analysis showing that
patients with cirrhosis did have a similarly increased risk of PVT
compared with non-cirrhotic patients without comorbidities;
however, the risk of developing DVT/PE was low when compared
with patients matched for morbidity and risk index (ie subjects
with chronic renal failure).20
A summary of the three cohort studies dedicated to evaluate the
incidence of DVT/PE in cirrhotic patients is represented in
Table 2.
Role of the aetiology of liver disease as a risk
factor for the development of DVT/PE
Northup and colleagues are the only group to have analysed the
role of liver disease aetiology as a risk factor for DVT/PE, but they
did not demonstrate any difference in the incidence of VTE in
patients with different aetiologies.13 However, patients with
autoimmune liver disease have been shown to have a higher inci-
dence of portal vein thrombosis compared with other aetiologies22
and patients with cholestatic liver disease are characterized by a
hypercoagulable state as evidenced by thromboelastography
(TEG) in about 50% of cases.23 Moreover, patients with cholestatic
aetiology of liver disease were characterized as having enhanced
thrombin generation as estimated by TEG at baseline before liver
transplantation compared with non-cholestatic cirrhotics.24
This hypercoagulable state can be seen as increased platelet
activation visible on the TEG trace.23 A further experimental study
has demonstrated hyperactivation of platelets in patients with
cholestatic liver disease compared with other aetiologies of cir-
rhosis. This may be as a result of the effect of chronic exposure to
high levels of bilirubin which can increase platelet adhesion.25
Moreover, increased levels of von Willebrand factor have been
described in cholestatic liver diseases.25
In accordance with these findings, patients with cholestatic
liver disease show less bleeding and less fibrinolysis during liver
transplantation;5,24 however, a study by Northup did not show a
higher incidence of thromboembolic complications in this
group.13
Moreover, Sogard and colleagues pointed out that even patients
with non-cirrhotic liver disease are at greater risk of DVT/PE
occurrence. This can be because of the high prevalence of addi-
tional risk factors such as obesity and diabetes amongst this
category of patients of non-alcoholic liver disease.19 Themetabolic
syndrome and non-alcoholic fatty liver disease have been associ-
ated with a greater risk of atherosclerosis and endothelial dysfunc-
tion which are thought to contribute to the prothrombotic state.26
Furthermore, insulin resistance correlates with increased platelet
adhesion, increased tissue factor and factor VII, and hypofibrin-
olysis as a result of high PAI-1 levels.27
Finally, patients with hepatocellular carcinoma are known to
be at greater risk of thromboembolic complications (i.e. portal
vein thrombosis and PE), and increased levels of thrombin–
antithrombin complexes have been demonstrated.28
Risk factors for the development of DVT/PE in
patients with liver cirrhosis
Surprisingly, standard coagulation laboratory parameters are not
associated with the risk of developing DVT/PE. In particular, INR
was not associated with thrombosis risk in the multivariate analy-
ses of Gulley et al.20 and Northup et al.13 and the mean INR value
in cirrhotic patients with DVT was similar to those of the two
other studies in the study of Garcia-Fuster and colleagues.21 This
reinforces the notion that the perceived coagulopathy in patients
with liver disease, as reflected in prolonged INR values, does not
protect patients against venous thrombosis.
Table 2 Incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with liver cirrhosis in published studies
Author Type of study Numer of
patients
analyzed
Incidence
of DVT/PE
% of patients
thromboprophylaxis
DVT
number (%)
PE number
(%)
DVT+PE
number (%)
Northup et al. (2006)13 Case–control 21.000 113 (0.5%) 21% (7% on medical
prophylaxis)
74 (65.5%) 22 (19.5%) 17 (15%)
Garcia-Fuster et al. (2008)21 Retrospective 2074 17 (0.8%) NA 10 (59%) 6 (35%) 1 (6%)
Gulley et al. (2008)20 Case–control 963 18 (1.87%) 0% NA NA NA
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Multivariate analysis to analyse risk factors for the development
of thrombosis was performed in two of the three dedicated stud-
ies.13,20 Serum albumin level was independently associated with
the occurrence of thrombosis in both of them. In the study by
Gulley et al., the mean albumin level in cirrhotic patients with
DVT was 2.7 0.6 g/dl., similar to mean serum levels in cirrhotic
patients with DVT in the retrospective series in Spain and USA.
Although the severity of liver disease assessed by Child–Pugh
and model for end-stage liver disease (MELD) scores was not
directly correlated with the risk of developing thromboembolic
complications, the evidence of the link with decreased hepatic
synthetic function as reflected by albumin levels is in keeping with
the hypothesis that the concomitant reduction of pro- and anti-
coagulant factors (antithrombin, protein C and S) can reset
the balance to a new precarious equilibrium which can be easily
disturbed.
Patients with cirrhosis and DVT/PE may share the same risk
factors as other non-cirrhotic patients with thrombotic compli-
cations such as venous stasis, infection, congestive heart failure,
acute respiratory disease and immobilization.20 Surgery and, in
particular, orthopaedic surgery is one of the major risk factors for
VTE in cirrhotic patients. In the cirrhotic patient, liver resection
such as for hepatocellular carcinoma has been shown to correlate
with a higher incidence of thrombotic complications (PE 7% in
127 living donors). It is correlated with a prothrombotic state
when evaluated by TEG up to 10 days after surgery despite anti-
thrombotic prophylaxis with Low molecular weight heparin
(LWMH).29 In fact, during hepatic resection, thrombin–
antithrombin complexes are elevated and this effect can be seen
up to the 7th day after surgery as a hypofibrinolytic state, even
during thromboprophylaxis with LMWH.30
Thrombotic prophylaxis in patients with liver
cirrhosis
Current guidelines on antithrombotic prophylaxis do not specifi-
cally comment on the cirrhotic population.31 Despite a lack of
specific guidelines, there has been a reduction in thromboembolic
complications in patients with liver cirrhosis in the past decade as
a result of an increase in the use of thromboprophylaxis. The lack
of specific guidelines for cirrhotic patients is because of the per-
ceived risk of bleeding complications, owing to potential abnor-
mal coagulation laboratory tests and the concomitant presence of
risk of portal hypertensive bleeding. Cirrhosis is thus considered
to be a relative contraindication for thrombophrophylaxis by
some centres. In the largest series that reported on the use of
anticoagulation in patients with PVT and liver cirrhosis, Francoz
et al. described 19 patients on the waiting list for liver transplan-
tation who underwent anticoagulation therapy, obtaining reca-
nalization in 42% without additional bleeding complications.32
However, only four patients had advanced liver disease (Child C),
and the severity of the portal hypertension was not well described
by the authors.
Garcia-Fuster and co-workers described the need for antico-
agulation in treating DVT in 17 patients with liver cirrhosis.21
Eleven out of 17 were treated with LWMH, and the remaining six
started with LWMH and switched to acenocoumarol thereafter.
There was an 83% incidence of bleeding amongst which 35%
needed transfusion and only three patients were able to complete
the treatment by 3 months. The grade and severity of portal
hypertension was not reported by the authors. We treated 38
cirrhotic patients with portal vein thrombosis (12 Child C, 20
Child B and 6 Child A) with LMWH, independent of coagulation
parameters, tailoring the LMWH dose according to platelet count.
There were two bleeding complications; one variceal bleed from
non-high-risk oesophageal varices and one intracranial haemor-
rhage which was self-limited in a patient older than 60 years with
no additional risk factors for bleeding.33
Current American College of Chest Physicians (ACCP) guide-
lines for thromboprophylaxis in patients with important risk
factors for bleedings state: ‘for medical patients with risk factors
for VTE, and for whom there is a contraindication to anticoagu-
lant thromboprophylaxis, we recommend the optimal use of
mechanical thromboprophylaxis with graduated compression
stockings or intermittent pneumatic compression’.31 The state-
ment has the maximum grade of evidence and strength of recom-
mendation, therefore it should be considered in cirrhotic patients
with high-risk varices.
One disadvantage of the use of LMWH and fondaparinux in
patients with cirrhosis, is the unpredictable efficacy, as these drugs
require antithrombin to exert its anticoagulant function, and anti-
thrombin levels are frequently decreased in these patients. The use
of the new incoming antithrombotic agents, directly inhibiting
factor (F)Xa or thrombin, will need very careful evaluation in this
subset of patients due to the risk of haemorrhagic complications.
The FXa inhibitors rivaroxaban and apixaban are metabolized in
the liver and they are contraindicated in severe hepatic diseases
because their metabolic inactivation is impaired. Metabolic
conversion of the prodrug dabigatran etexilate to dabigatran, a
thrombin inhibitor, is completed in the liver and followed by
partial biliary excretion of a conjugated derivate. Idraparinux, an
antithrombin dependent FXa inhibitor, has no hepatic clearance,
but its long half-life (approximately 80 h) and the lack of antidote
do represent major problems if bleeding occurs. Finally, all these
drugs must be used with caution or are contraindicated in the
presence of renal failure.
Conclusions
Nowadays, patients with cirrhosis and liver disease cannot be
considered as auto-anticoagulated, because of the clear evidence
of the occurrence of thrombotic events with an appreciable inci-
dence of DVT and PE not different from other chronic diseases,
despite abnormal standard coagulation tests. The natural reset of
the haemostatic balance to a lower level can be easily disturbed by
both prohaemorrhagic and prothrombotic conditions. In particu-
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lar, patients with liver cirrhosis share the same risk factors for
thrombosis as the general population, with orthopaedic surgery,
liver resection and immobilization being the most represented
precipitating conditions.
Therefore, thromboprophylaxis should be recommended in
patients with liver cirrhosis at least when exposed to high-risk
conditions for thrombotic complications. LWMHs seem to be
relatively safe in this group of patients, however, when important
risk factors for bleeding are present, graduated compression
stockings or intermittent pneumatic compression should be
considered.
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